| Volume: | 3,444,409 |
|---|---|
| Day's Low: | $28.93 |
| 52-wk Low: | $18.37 |
| Previous Close: | $29.11 |
| Dividend: | $0.00 |
| Market Cap: | 8,923,200 |
| Avg Volume: | 2,560,300 |
|---|---|
| Day's High: | $29.62 |
| 52-wk High: | $30.56 |
| Open Price: | $29.19 |
| Yield: | 0.00% |
| P/E (Forward): | 8.55 |
| 12:11 PM | 11/17/2009 | Forest Labs President Prefers Drug Partnerships, Not Big M&A |
| 8:04 PM | 11/16/2009 | UPDATE: Icahn Reports New Stakes In Genzyme, Forest Labs |
| 7:03 PM | 11/16/2009 | Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30 |
| 11:59 AM | 11/9/2009 | Forest Labs In Tentative Pact To Settle US Civil Probe |
| 5:40 AM | 10/29/2009 | Richter To Start Late Stage Tests On Key Schizophrenia Drug |
| 4:32 AM | 10/29/2009 | Hungary Richter, US Forest Announce Positive Drug Tests |
| 10:06 AM | 10/20/2009 | Forest Labs 2Q Net Drops 23% On Charges; Results Beats Views |
| 11/17/2009 | Market-trouncing returns could be written in these stars. |
| 11/16/2009 | Here's where the experts are placing their bets for next year. |
| 10/21/2009 | Forest Labs' Shares Out of the Woods |
| 10/20/2009 | Updates, advisories and surprises |
| 10/20/2009 | Drug stocks follow broader market lower |
| 10/1/2009 | 3 Stocks Poised to Outperform |
| 8/12/2009 | Forest leads drug shares higher on antibiotic deal |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.85 | 0.80 | 6.25 |
| EPS, GAAP | 0.61 | 0.80 | -23.75 |
| Consensus Estimate | 0.85 | 0.69 | 23.19 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 3.51 | 3.46 | 1.45 |
| EPS, GAAP | 2.41 | 3.10 | -22.26 |
| Consensus Estimate | 3.18 | NA | NA |
| FRX | Industry Average | |
| P/E (TTM) | 12.27 | 81.60 |
| P/E (Forward) | 8.55 | 1.10 |
| PEG Ratio | 1.77 | 0.07 |
| Price/Sales | 2.23 | 3.90 |
| Beta | 0.74 | 0.68 |